Safety and efficacy of repaglinide in combination with metformin and bedtime NPH insulin as an insulin treatment regimen in type 2 diabetes

What Was Tested

The paper reports a study of NPH Insulin (isophane), published as a randomized controlled trial.

Who Took Part

According to the abstract, 24 patients were involved.

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

Random, parallel and open study of 24 weeks with 37 patients randomized into three therapeutic groups: group A (n=12) (repaglinide/metformin/NPH), group B (n=12) (metformin/NPH) and group C (n=13) (NPH/NPH).

The endpoint criteria included HbA1c, blood glucose profile, hypoglycemias and body weight.

How the Study Was Run

The researchers set it up as a randomized and parallel-group study.

The patients were allocated by chance, so the NPH Insulin (isophane) group and the comparison group should start out alike.

The NPH Insulin (isophane) group and the comparison group ran side by side rather than switching.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Blood Pressure, Body Mass Index, Carbamates, Diabetes Mellitus, Type 2, Glycated Hemoglobin and Insulin, Isophane.

What This Means in Plain Language

The paper is a randomized and parallel-group study of NPH Insulin (isophane) in 24 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2008 (Diabetes research and clinical practice), a journal based in Ireland.

More context: the NPH Insulin (isophane) compound page, all human trials.